Genmab has seen significant investor activity, with numerous acquisitions of their shares, including Principal Securities Inc., Trexquant Investment LP, Envestnet Portfolio Solutions Inc., Aigen Investment Management LP, International Assets Investment Management LLC, and Simplicity Wealth LLC. Additionally, HC Wainwright maintains a 'Buy' rating for Genmab, suggesting strong standing in the market. Despite some drop in stock prices and reported fluctuations, the company forecasts are positive. Genmab has undertaken a share buy-back program and granted restricted stock units to board members and employees. Furthermore, Q1 2024 earnings beat expectations on revenue. Recently, Genmab completed a large-scale acquisition of ProfoundBio, a developer of ovarian cancer drugs, despite this causing a temporary slump in their stock. Their focus and financial strategy go beyond 2024, with plans for continued growth and strong performance in biotech sector.
Genmab Stocks News Analytics from Tue, 23 Apr 2019 07:00:00 GMT to Thu, 23 May 2024 19:25:13 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor -1
